TK1 has long been used as a diagnostic and prognostic marker in AML (O'Neill et al., 2007), and PCMTD2 (Atkins et al., 2019) and LRRC40 (Zeybek et al., 2019) have been used as diagnostic or prognostic markers in other types of cancer. Here, TK1 is linked to acute myeloid leukemia.